阳性无otropic疗法对血液动力学和器官功能在急性心力衰竭的影响:一个差异化的观点
Juan Cheko1, Nikolaos Patsalis1, Julian Kreutz1
1Department of Cardiology, Angiology, and Intensive Care Medicine, Hospital of the Phillips University of Marburg, D-35043 Marburg, Germany.
Journal of personalized medicine
|January 22, 2024
概括
积极的内类药物改善了急性不补偿性心力衰竭 (HF) 的结果. 患有扩张性心肌病 (DCM) 的患者,接受了levosimendan治疗,以及那些处于鼻腔节律/心脏起器节律 (SR/PM) 的患者显示出最大的益处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 在急性不补偿性心力衰竭 (HF) 中,对内药对血液动力学,生物标志物和末端器官功能的影响的理解有限.
- 肝炎呈现出不同的病因和心律,使治疗反应评估复杂化.
研究的目的:
- 调查异能药物 (dobutamine,levosimendan) 对急性不补偿性HF患者血液动力学,生物标志物和功能的影响.
- 为了确定患者亚组,最受益于无otropic 治疗.
主要方法:
- 对50名急性失补偿性HF患者的前性研究 (扩张性心肌病 [DCM],缺血性心肌病 [ICM],心房动 [AF],鼻节律/心脏起器 [SR/PM]).
- 用dobutamine或levosimendan.com进行治疗.
- 评估非侵入性血液动力学,NT-proBNP/ST2生物标志物,和估计的膜过率 (eGFR) 在入院和5-7天.
主要成果:
- 整体队列显示体重和生物标志物 (NT-proBNP/ST2) 减少,EGFR增加.
- 血液动力学改善在DCM患者,levosimendan亚组和SR/PM患者中最明显.
- 在整个队列中观察到功能 (eGFR) 的显著改善.
结论:
- 短期积极的内托普疗法对急性失补偿性HF患者有好处.
- DCM患者,接受levosimendan的患者和SR/PM患者似乎获得了最大的益处.
- 无otropic疗法可以改善急性失补偿性HF的功能.
更多相关视频
06:22Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
Published on: September 17, 2015
15.0K
08:49Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
750
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
01:22Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:29Pathophysiology of Cardiac Performance
665
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
665